Aomori, Tohru

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 病院薬学講座 (Shiba-Kyoritsu)

Position

Associate Professor

 

Books 【 Display / hide

  • 「アンサングシンデレラ」・「治療薬マニュアル」コラボ小冊子

    青森達, 医学書院, 2020

  • 老年医学(上)-基礎・臨床研究の最新動向-

    青森達, 望月眞弓, 日本臨牀社, 2018

    Contact page: 347-353

  • 早期臨床体験テキスト

    AOMORI Tohru, ネオメディカル, 2017

  • 精神科領域におけるEBP. Progressive Pharmacist

    AOMORI Tohru, 2010

  • 薬剤師による処方支援 ワルファリン投与における処方支援

    AOMORI Tohru, 医薬ジャーナル, 2008

display all >>

Papers 【 Display / hide

  • 診療科間における情報共有を可能とした妊娠・授乳と薬相談業務の取組み

    鈴木靖奈, 三浦あす美, 滝澤詠美子, 杉谷綾佳, 西木美優, 川島沙織, 櫻井しおり, 潮田佳奈,玉川知鮎, 清宮啓介, 小谷宙, 山吉康子, 村松博, 青森達

    日本病院薬剤師会雑誌 58   408 - 415 2022.03

    Research paper (scientific journal), Joint Work, Last author, Accepted

  • 薬学教育モデル・コアカリキュラムに基づく実務実習におけるルーブリック形式の概略評価は実習生のパフォーマンスレベルを測定できるか?

    河添仁, 鈴木小夜, 平賀ゆい, 横山雄太, 地引綾, 岩田紘樹, 小林典子, 藤本和子, 中田英夫,青森達, 山浦克典, 中村智徳

    医療薬学 47   513 - 524 2021.09

    Research paper (scientific journal), Joint Work, Accepted

  • Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: A multicenter retrospective study using three propensity score analyses

    Arami T., Kawazoe H., Uozumi R., Hashimoto H., Egami S., Sakiyama N., Ohe Y., Nakada H., Aomori T., Ikemura S., Yasuda H., Kawada I., Fukunaga K., Soejima K., Yamaguchi M., Nakamura T.

    Pharmazie (Pharmazie)  76 ( 6 ) 266 - 271 2021.06

    ISSN  00317144

     View Summary

    Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion transporters. Thus, this study aimed to clarify whether RAS inhibitors (RASIs) could prevent pemetrexed plus platinum-induced hematological toxicities. We retrospectively analyzed data from 305 consecutive patients with non-small cell lung cancer or malignant pleural mesothelioma who received their first cycle of a pemetrexed plus platinum regimen and were treated with or without RASIs. The primary endpoint was the incidence of severe myelosuppression after the first cycle. Propensity score (PS)-matched, PS-adjusted, and inverse probability of treatment weighting (IPTW) analyses were used. The number of patients with grade ≥3 hematological toxicities was 27 (8.9%). PS-matched analyses revealed that the concomitant use of RASIs was slightly associated with a lower risk of grade ≥3 hematological toxicities (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.20-2.32; p = 0.536). Additionally, sensitivity analyses using PS-adjusted and IPTW methods demonstrated similar results (OR, 0.63; 95% CI, 0.19-2.15; p = 0.463 and OR, 0.37; 95% CI, 0.11-1.29; p = 0.117, respectively). These findings suggest that RASIs might prevent pemetrexed plus platinum-induced hematological toxicities.

  • Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study

    Egami Saeka, Kawazoe Hitoshi, Hashimoto Hironobu, Uozumi Ryuji, Arami Toko, Sakiyama Naomi,Ohe Yuichiro, Nakada Hideo, Aomori Tohru, Ikemura Shinnosuke, Fukunaga Koichi, Yamaguchi Masakazu, Nakamura Tomonori

    Frontiers in Oncology (Frontiers in Oncology)  11 2021.05

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    Background: Among patients with advanced non-small-cell lung cancer who were treated with nivolumab monotherapy, the association of peripheral blood count data (at baseline and 2 weeks after treatment initiation) with the early onset of immune-related adverse events (irAEs) and treatment efficacy has not been clearly established. This study aimed to identify peripheral blood count data that may be predictive of the development of nivolumab-induced irAEs in a real-world clinical setting. Materials and Methods: This multicenter observational study retrospectively evaluated consecutive patients with advanced non-small-cell lung cancer undergoing nivolumab monotherapy in the second- or later-line setting between December 2015 and November 2018 at the National Cancer Center Hospital and Keio University Hospital in Japan. The primary endpoint was the association between peripheral blood count data and irAEs during the 6-week study period. Receiver operating characteristic curve and multivariable logistic regression analyses were performed. Results: Of the 171 patients evaluated, 73 (42.7%) had ≥1 irAE during the first 6 weeks following treatment initiation. The median time to irAEs from the initiation of nivolumab was 15 (interquartile range: 13–28) days. Receiver operating characteristic curve analyses revealed that the optimal cut-off values of the absolute lymphocyte count, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio 2 weeks after treatment initiation for early irAE onset were 820, 4.3, and 2.2, respectively. In multivariable logistic regression analyses, absolute lymphocyte count >820 at 2 weeks after treatment initiation was significantly associated with an increased risk of early onset of any irAE. In contrast, no significant association was observed for the neutrophil-to-lymphocyte ratio (>4.3) or the lymphocyte-to-monocyte ratio (>2.2) at 2 weeks following treatment initiation. Conclusions: The absolute lymphocyte count >820 at 2 weeks following nivolumab initiation predicts early onset of irAEs during a 6-week study period. Routinely available absolute lymphocyte count, which is measured after the initiation of nivolumab, may be useful for identifying patients at risk of early onset of irAEs.

  • Effect of a lever aid on hand strength required for using a handheld inhaler correctly

    Nakada Hideo, Aomori Tohru, Mochizuki Mayumi

    International Journal of Pharmaceutics (International Journal of Pharmaceutics)  596 2021.03

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  03785173

     View Summary

    © 2021 The Author(s) In the treatment of asthma and chronic obstructive pulmonary disease, using a lever aid to improve drug delivery from an inhaler is recommended for patients with poor muscle strength. However, no studies have investigated the effect on hand strength of using a lever aid. Here, we measured hand strength before and after operating a lever aid and tried to predict the required strength. We compared the pinch force required to activate a pressurized metered dose inhaler (pMDI) and a dry powder inhaler as well as the rotational torque required to activate a soft mist inhaler (SMI) before and after attaching a lever aid. We then assessed the correlation between the theoretical and measured pinch force after fitting the lever aid. Use of the lever aid significantly reduced the pinch force required for pMDI operation from 26.13–48.74 N to 4.90–16.87 N. In contrast, using a lever aid significantly reduced the force needed to rotate SMI, although the rotational torque required to operate did not change. There was a significant positive correlation between the theoretical and measured pinch forces required to activate a pMDI fitted with a lever aid. Using a lever aid will increase the number of patients who can use this device.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • Cancer genomic medicine in Japan and the roles of pharmacists

    Aomori Tohru, Sakurai Hiroomi, Nishihara Hiroshi

    Pharmacogenetics and Genomics  2022

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Lead author, Corresponding author

  • Genomic medicine from a team approach and the role of pharmacists

    Aomori T., Mochizuki M.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 5 ) 649 - 650 2020.05

    ISSN  00316903

Presentations 【 Display / hide

  • HIV感染症外来におけるPBPM実施の効果

    神成はるか, 西松直美, 小谷宙, 村松博, 青森達, 大谷壽一

    日本医療薬学会 第5回フレッシャーズ・カンファランス, 

    2022.06

    Oral presentation (general)

  • ヒドロモルフォンの注射剤から経口剤への換算比の検討

    傳田容子, 金子健, 袴田潤, 坂本麻味, 滝澤詠美子, 大野あゆみ, 伊原奈帆, 瀧野陽子, 大岸美和子, 青森達, 大谷壽一, 竹内麻理

    第15回日本緩和医療薬学会年会, 

    2022.05

    Poster presentation

  • ナルデメシジンの有効性と予後予測ツールで評価した全身状態との関係

    滝澤詠美子, 金子健, 袴田潤, 坂本麻味, 傳田容子, 伊原奈帆, 瀧野陽子, 大岸美和子, 青森達, 大谷壽一, 竹内麻理

    第15回日本緩和医療薬学会年会, 

    2022.05

    Poster presentation

  • 薬剤師を対象としたノセボ作用の認知度に関するアンケート調査

    間宮桐子, 井澤美苗, 石川春樹, 中田英夫, 富永佳子, 望月眞弓, 青森達

    日本薬学会第142年会, 

    2022.03

    Oral presentation (general)

  • MeDaCa® アプリを活用した妊娠・授乳と薬相談 -オンライン相談の取り組み-

    櫻井しおり, 三浦あす美, 鈴木靖奈, 小谷宙, 清宮啓介, 村松博, 青森達, 大谷壽一

    日本薬学会第142年会, 

    2022.03

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • AI を用いた医薬品の未承認・禁忌・適応外使用データベースの構築と医療安全への応用

    2019

    2019年度慶應義塾学事振興資金(個人研究), 青森達, Research grant, Principal investigator

  • 慢性呼吸器疾患治療の高度化と標準化に向けた吸入動作評価技術の開発研究

    2019

    日本医療研究開発機構研究費, 橋渡し研究戦略的推進プログラム, Research grant, Coinvestigator(s)

  • 生活者にとって分かりやすい要指導・一般用医薬品添付文書の構成に関する研究

    2018
    -
    2020

    日本医療研究開発機構研究費, Commissioned research, Coinvestigator(s)

  • プラセボ効果の個体間変動要因:プラセボームとパーソナリティ解析による個別薬物療法

    2018
    -
    2020

    日本学術振興会科学研究費補助金, 基盤研究 (C), Research grant, Coinvestigator(s)

  • ゲノム医療従事者の育成プログラム開発

    2018
    -
    2020

    日本医療研究開発機構研究費, Commissioned research, Coinvestigator(s)

display all >>

Awards 【 Display / hide

  • 優秀演題賞

    富永佳子, 青森達, 早川智久, 井澤美苗, 望月眞弓, 2018.10, 第7回日本くすりと糖尿病学会学術集会, 糖尿病患者の服薬アドヒアランス不良リスク推定モデルの作成と介入支援ツールの構築 -患者への個別化対応実践のために-.

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 学生優秀発表賞

    富永佳子, 青森達, 早川智久, 望月眞弓, 2018.03, 日本薬学会第138年会,, 糖尿病患者におけるアドヒアランス影響因子に関する研究-内的要因としての病識に着目した探索的検討-

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 優秀発表賞

    菊山史博, 鈴木小夜, 高木彰紀, 地引綾, 横山雄太, 青森達, 中村智徳, 2017.09, 第2回日本薬学教育学会大会, 薬学実務実習が実習生の専門知識(C1~C18)の定着及び新規構築に与える影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 優秀ポスター発表賞

    羽田有里, 青森達, 坡下真大, 荒木拓也, 山本康次郎, 鈴木小夜, 地引綾, 中村智徳, 2015.09, 第59回日本薬学会関東支部大会, アプレピタントによる補助療法ががん化学療法の治療経過に与える影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第66回日本食道学会学術集会優秀ポスター演題賞(メディカルスタッフ)

    荒木聖美、長嶺 歩、青森 達、荒木拓也、飯塚恵子、田中成岳、浅尾高行、桑野博行、中村智徳、山本康次郎., 2012.06, 日本食道学会, 食道癌化学放射線療法における免疫栄養剤併用の有用性.

     View Description

     

display all >>

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (HOSPITAL PHARMACY SCIENCE)

    2022

  • SPECIALTY PHARMACISTS ACTIVE IN PERSONALIZED TREATMENT

    2022

  • SEMINAR: (HOSPITAL PHARMACY SCIENCE)

    2022

  • RESEARCH FOR BACHELOR'S THESIS 1

    2022

  • PRIOR LEARNING FOR CLINICAL PRACTICE 4

    2022

display all >>